1. On top of the dilution, they are now paying salespeople to sit around.
2. By not partnering with a major brand salespeople will only have one product to trot in to show doctors.
3. If there is a major issue with the distributor in India the FDA could shut this down until CEMP gets a distribution partner that meets FDA standards. If the active ingredient is not exactly the same all the previous trials, no matter how good they are and no matter the need for this anti biotic, could be shelved and new trials may be needed.
The risk here was very much in the open. I was vocal against all the dilution. The banks had a terrible year with underwritings and they sold CEMP lock stock and barrel on this dilution. It does not matter if the FDA loves the drug if there are issues with the active ingredient at the source.
Have made good trades here 3 times so CEMP doesn't owe us anything, but if they were offered in the 40's earlier in the year by a major partner they should have taken it.
Hope they figure this out quickly. It is bizarre that articles are being written about these issues without a press release. This is a material event if true
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM